The BMJ brings you interviews with the people who are shaping medicine and science around the world.
…
continue reading
Content provided by TheBody.com. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by TheBody.com or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
The Bottom Line on Isentress
MP3•Episode home
Manage episode 127240 series 2246
Content provided by TheBody.com. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by TheBody.com or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
On Oct. 12, the U.S. Food and Drug Administration approved Isentress, the first member of a new class of meds called integrase inhibitors. Isentress is also known generically as raltegravir, and during its early development was called MK-0518. To find out more about Isentress and how it might impact treatment for HIV-positive people, we spoke with Dr. David Wohl, an associate professor of medicine at the University of North Carolina-Chapel Hill, and the co-director of HIV services for the North Carolina Department of Corrections. Dr. Wohl has participated in research on Isentress, and has also received research funding from Merck and Company, which developed Isentress. This is Part I of an update on Isentress.
…
continue reading
77 episodes
MP3•Episode home
Manage episode 127240 series 2246
Content provided by TheBody.com. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by TheBody.com or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
On Oct. 12, the U.S. Food and Drug Administration approved Isentress, the first member of a new class of meds called integrase inhibitors. Isentress is also known generically as raltegravir, and during its early development was called MK-0518. To find out more about Isentress and how it might impact treatment for HIV-positive people, we spoke with Dr. David Wohl, an associate professor of medicine at the University of North Carolina-Chapel Hill, and the co-director of HIV services for the North Carolina Department of Corrections. Dr. Wohl has participated in research on Isentress, and has also received research funding from Merck and Company, which developed Isentress. This is Part I of an update on Isentress.
…
continue reading
77 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.